Cure8 research brief
Higher, optimised doses of prolonged-release mesalazine were linked with fewer clinical recurrences over 12 months in adults with mild-to-moderate UC, which could influence treatment decisions about mesalazine dose and formulation.
Adults with mild-to-moderate ulcerative colitis; clinicians prescribing mesalazine; patients interested in mesalazine dosing and formulation
This is a post-hoc analysis of the IMPACT phase 4, 12-month, non-interventional Dutch study (NCT02261636) that compared outcomes for patients prescribed prolonged-release mesalazine at 4 g/day versus 2–3 g/day. Most participants received 4 g/day, mainly as once-daily granules, and the recurrence rate was lower in the 4 g/day group (26.6% vs. 62.5%).
Adherence and formulation preference (granules, once daily) were reported as high. The analysis is observational and post-hoc, so it can show associations but cannot prove causation or replace randomized trial evidence. The full study methods and baseline differences between dose groups should be reviewed to understand potential confounding.
This is a post-hoc analysis of a non-interventional prospective study (phase 4). Observational design limits causal inference; baseline differences and reasons for dose selection could affect outcomes. The structured content here is based on the article abstract provided by the journal.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Ferring Pharmaceuticals
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This label update lists safety concerns that affect people taking mesalamine for ulcerative colitis, including the need for kidney monitoring, signs of hypersensitivity, and rare but serious skin and liver reactions.
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...
